HIGHLIGHTS
- who: Helena Polena from the (UNIVERSITY) have published the research: The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma, in the Journal: (JOURNAL)
- what: The aim of this study was to determine whether antiangiogenic treatment commonly used for the clinical care of mRCC had an effect on VE-cadherin post-translational modifications (i.e., phosphorylation and cleavage) and if so, whether such modifications were helpful to monitor patient outcome. Among the compounds tested, the authors demonstrate for the first time that the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.